AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15631278
Drug: Previous monotherapy
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous monotherapy (PM) plus hydrochlorothiazide (HCTZ) 12.5 mg
Trial: 11603446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 100 mL 0.9% NaCl solution (25 mL/h) at the same time points
Trial: 16105426
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy + NIPPV (Bi-level positive airway pressure mode)
Trial: 2074867
Drug: Nimesulide suppositories
RxNorm normalized name: nimesulide Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide suppositories
Trial: 7005654
Drug: Detartrasis alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detartrasis alone (not followed by regular oral hygiene)
Trial: 26350034
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group receiving: 28,000 IU cholecalciferol/wk for 8 weeks before surgery, 16,000 IU/wk and 1000 mg calcium monocitrate/d after surgery, daily BMI‐adjusted protein supplementation and physical exercise
Trial: 22917822
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (not administered landiolol hydrochloride)
Trial: 20430451
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (NS) treatment (same duration as intervention)
Trial: 16121634
Drug: Karyometric measurements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karyometric measurements from biopsies of rectal mucosa
Trial: 10889166
Drug: Lamivudine 100
RxNorm normalized name: lamivudine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine 100 mg daily for 2 years
Trial: 9364700
Drug: Combined DTPa-HBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DTPa-HBV vaccine
Trial: 9364700
Drug: Extemporaneously mixed
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extemporaneously mixed DTPa and HBV vaccines
Trial: 29388846
Drug: Low-dose extract
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose extract (400 mg/day)
Trial: 26190177
Drug: R-A/L-C (anodal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-A/L-C (anodal electrode placed over the right SMC and cathodal electrode over the left SMC)
Trial: 24742019
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of each institution
Trial: 16670112
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 40 mg kg(‐1) i.v. as a bolus before induction and 15 mg kg(‐1) h(‐1) by continuous i.v. infusion during the operation
Trial: 14563595
Drug: Low-dose metoprolol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose metoprolol (up to 10 mg)
Trial: 11068993
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication treatment (2-week triple therapy: amoxicillin, clarithromycin, omeprazole)
Trial: 31533391
Drug: 7.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg tranexamic acid before upper tourniquet and after closure of incision, combined with flexion position of hip (30° to 45°) and knee (60° for 70°)
Trial: 31533391
Drug: 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg tranexamic acid injected before loosening tourniquet
Trial: 19218297
Drug: Robot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot therapy with physiotherapy (10 sessions, more than 5000 movements)
Trial: 19218297
Drug: Robot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot therapy with physiotherapy
Trial: 11408508
Drug: Raloxifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 120 mg/d
Trial: 9600478
Drug: HRT (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 2.5 mg/d)
Trial: 8273794
Drug: 4 x/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x/day therapy of CBS (108 mg), tetracycline HCl (500 mg), and metronidazole (250 mg)
Trial: 2537217
Drug: Trandolapril (0.125,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 24, 32 mg)
Trial: 4983855
Drug: Ampicillin or
RxNorm normalized name: ampicillin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin or no antibiotic
Trial: 21301920
Drug: Methylprednisolone in
RxNorm normalized name: methylprednisolone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone in combination with azathioprine (MP + Aza group)
Trial: 19156159
Drug: Calcium-vitamin D(3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-vitamin D(3) fortified milk (400 ml per day, approximately 1000 mg of calcium and 800 IU of vitamin D(3))
Trial: 17474812
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (assertive outreach community treatment, family psychoeducation, social skills training)
Trial: 16377455
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment
Trial: 18485612
Drug: Individual-Based Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-Based Treatment (IBT)
Trial: 17716321
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNTA) injection into frontal (10 U)
Trial: 17716321
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNTA) injection into temporal (6 U)
Trial: 17716321
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNTA) injection into glabellar (9 U)
Trial: 17716321
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BoNTA) injection into all three areas (total dose 25 U)
Trial: 31718959
Drug: No bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bonding agent
Trial: 31718959
Drug: Pre‐treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐treatments
Trial: 21778605
Drug: Bonding agent
RxNorm normalized name: SKIN BOND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bonding agent
Trial: 31718959
Drug: Interaction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interaction of pre‐treatments and bonding agent
Trial: 28552806
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination
Trial: 23265711
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus chemotherapy
Trial: 28595137
Drug: Control (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (chemotherapy without cetuximab)
Trial: 9401097
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide (50 mg) taken orally t.i.d. with food
Trial: 3620281
Drug: 0.8 g
RxNorm normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 g kg‐1 absolute ethanol orally
Trial: 21256028
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose of vitamin D (880 IU/d)
Trial: 21256028
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of vitamin D (1600 IU/d)
Trial: 18729731
Drug: Vitamin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin therapy
Trial: 7839898
Drug: Cyclophosphamide 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 600 mg/m2 intravenously (i.v.) on day 1
Trial: 7839898
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of i.v. cyclophosphamide 600 mg/m2 on day 1 and cytosine arabinoside 100 mg/m2 12 hourly sc for days 1‐5
Trial: 20565392
Drug: 0.568 mg
RxNorm normalized name: petrolatum 0.568 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.568 mg x ml(‐1) levobupivacaine plus sufentanil 0.45 microg x ml(‐1)
Trial: 20565392
Drug: 1.136 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.136 mg x ml(‐1) levobupivacaine plus sufentanil 0.45 microg x ml(‐1)
Trial: 16943467
Drug: Initial injection
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial injection of 30 ml of levobupivacaine 0.5% with adrenaline 1:200 000.
Trial: 16943467
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of levobupivacaine 0.25% at a rate of 5 ml per hour after an initial injection of 30 ml of levobupivacaine 0.5% with adrenaline 1:200 000.
Trial: 8571186
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin prophylaxis
Trial: 7259512
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium chloride (0.5 mg/kg/min constant infusion)
Trial: 18355325
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg once daily
Trial: 23988802
Drug: Epidural corticosteroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural corticosteroid injection of 80 mg methylprednisolone acetate
Trial: 23988802
Drug: Epidural corticosteroid
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural corticosteroid injection of 40 mg methylprednisolone acetate
Trial: 23928873
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance therapy
Trial: 15136320
Drug: High-dose antioxidants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose antioxidants
Trial: 11181667
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg/m(2)/d
Trial: 11181667
Drug: Dexamethasone 18
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 18 mg/m(2)/d
Trial: 11181667
Drug: Dexamethasone 150
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 150 mg/m(2)/d
Trial: 11181667
Drug: Standard-dose corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose corticosteroids (prednisolone 40 mg/m(2)/d or dexamethasone < 6 mg/m(2)/d)
Trial: 9134141
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg, maximum dose 12 mg)
Trial: 3428347
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 750 mg theophylline (2 capsules Euphylong 375)
Trial: 3428347
Drug: Intravenous aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminophylline infusion corresponding to 506 mg theophylline over 8 h (63 mg.h‐1)
Trial: 6240568
Drug: GRF1-44 (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GRF1-44 (administered over 2 days in 6- and 18-h intervals)
Trial: 15982350
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of influenza vaccine
Trial: 23650780
Drug: BOMT1 (Bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOMT1 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 2 x 500 mg, tetracycline 2 x 500 mg; for 14 days)
Trial: 23650780
Drug: BOMT2 (Bismuth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOMT2 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 3 x 500 mg, tetracycline 4 x 500 mg; for 14 days)
Trial: 11289483
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin combined with glibenclamide (n = 19)
Trial: 11289483
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin combined with metformin (n = 17)
Trial: 11289483
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin combined with glibenclamide and metformin (n = 17)
Trial: 11289483
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of NPH insulin (n = 23)
Trial: 20378197
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin therapy
Trial: 3217756
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 800 mg/day
Trial: 3217756
Drug: S-adenosyl-L-methionine (SAMe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine (SAMe) 200 mg/day
Trial: 23974642
Drug: Tafamidis 20
RxNorm normalized name: TAFAMIDIS 20MG TAB UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 20 mg once daily
Trial: 21419776
Drug: Whole inactivated
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole inactivated vaccines
Trial: 21419776
Drug: Subunit vaccines
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccines
Trial: 19195817
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of epirubicin 75 mg/m² and docetaxel 75 mg/m²
Trial: 11583478
Drug: GW420867X 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 1200 mg
Trial: 2607268
Drug: 1.8 ml
RxNorm normalized name: insulin pump syringe, 1.8 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Trial: 2607268
Drug: 3.6 ml
RxNorm normalized name: ALCOHOL 2.7 mL in 3.6 mL TOPICAL CLOTH [hand sanitizers]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 ml of 2% lidocaine with 1:200,000 epinephrine
Trial: 30684002
Drug: High-dose RAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose RAI therapy (3700 MBq)
Trial: 30684002
Drug: Low-dose RAI
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RAI therapy (1110 MBq)
Trial: 28632666
Drug: Low-Intensity Pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) treatment for 2 minutes a day at 100 KHz frequency
Trial: 19694184
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as ER capsules
Trial: 19694184
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as plain capsules
Trial: 19694184
Drug: Budesonide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (3 mg) without grapefruit juice
Trial: 16973647
Drug: Ropivacaine 0.2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2%, 1 ml kg(‐1) with fentanyl 1 microg kg(‐1)
Trial: 16973647
Drug: Ropivacaine 0.2%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2%, 1 ml kg(‐1) with saline
Trial: 11139102
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion (0.3 microg/kg/h)
Trial: 11139102
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion plus intrathecal morphine
Trial: 31288863
Drug: Sufentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil infusion
Trial: 9417395
Drug: Hydroxyzine 50
RxNorm normalized name: hydroxyzine hydrochloride 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 50 mg, abrupt or progressive withdrawal
Trial: 1348430
Drug: Neuroleptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic treatment (dosage changed)
Trial: 3254767
Drug: Oral high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral high-frequency oscillation (OHFO)
Trial: 25530160
Drug: Intradermal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal capsaicin injection at 1 mm depth
Trial: 25530160
Drug: Intradermal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal capsaicin injection at 3 mm depth
Trial: 25530160
Drug: Intradermal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal capsaicin injection at 5 mm depth
Trial: 25530160
Drug: Intradermal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal capsaicin injection at 7 mm depth
Trial: 12850864
Drug: Metformin, 850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, 850 mg twice daily throughout the cycle
Trial: 8998891
Drug: Ketorolac (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac (60 mg followed by 30 mg)
Trial: 8998891
Drug: Meperidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (100 mg or placebo)
Trial: 2007041
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg IV
Trial: 2007041
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg IV and Metoclopramide 10 mg IV
Trial: 29098908
Drug: Desoximetasone 0.25%
RxNorm normalized name: DESOXIMETASONE 0.25% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone 0.25% topical spray
Trial: 16673804
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% spray
Trial: 18645542
Drug: J‐Tip jet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: J‐Tip jet injection of 1% buffered lidocaine
Trial: 18645542
Drug: Topical 4%
RxNorm normalized name: menthol topical 4% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 4% ELA‐Max
Trial: 16585868
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel and cisplatin (25 mg/m cisplatin and 35 mg/m docetaxel once a week for 3 weeks followed by 1 week without treatment)
Trial: 16585868
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel and cisplatin
Trial: 11843382
Drug: Levonorgestrel implants
RxNorm normalized name: levonorgestrel Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel implants
Trial: 25493596
Drug: Monthly dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly dihydroartemisinin-piperaquine
Trial: 27076184
Drug: Daily trimethoprim-sulfamethoxazole
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily trimethoprim-sulfamethoxazole
Trial: 7003032
Drug: Amantadine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (200 mg/day)
Trial: 1728688
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 gm before operation and 500 mg every 4 hours during operation)
Trial: 6741802
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 to 50 mg)
Trial: 20395917
Drug: Sub-conjunctival injection
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-conjunctival injection of dexamethasone and gentamicin combination (Group A)
Trial: 17504616
Drug: Physio-psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physio-psychological treatment
Trial: 17504616
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (DDAVP tablets)
Trial: 2062626
Drug: Schwarz strain
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz strain measles vaccine (control)